Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Seth, Arjun ^a   Ritchie, Fiona K ^a   Wibowo, Nani ^a   Lua, Linda H L ^a   Middelberg, Anton P J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; PEPTIDE VACCINE; POLYCAPROLACTONE; POLYGLACTIN; SILICON DIOXIDE; HEPATITIS A ANTIBODY; INFLUENZA VACCINE; LACTIC ACID; MATRIX PROTEIN; PHARMACEUTICAL VEHICLES AND ADDITIVES; POLYESTER; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

AMINE FUNCTIONALIZATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CHEMICAL MODIFICATION; CYTOKINE RELEASE; DRUG FORMULATION; DRUG MIXTURE; FEMALE; IMMUNOGENICITY; IMMUNOREGULATION; IN VIVO STUDY; INFLUENZA A VIRUS; MOUSE; NONHUMAN; PEGYLATION; SPLEEN CELL; SURFACE PROPERTY; VIRUS CAPSID; VIRUS CAPSOMERE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ANIMALS; FEMALE; HEPATITIS A ANTIBODIES; INFLUENZA VACCINES; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYESTERS; POLYGLYCOLIC ACID; SILICON DIOXIDE; SURFACE PROPERTIES; VIRAL MATRIX PROTEINS;

EID: 84959274756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117203     Document Type: Article

References (61)

1. Plotkin SL, Plotkin SA (2004) A short history of vaccination. Vaccines 5: 1-16.
2. Peek LJ, Middaugh CR, Berkland C (2008) Nanotechnology in vaccine delivery. Advanced drug delivery reviews 60: 915-928. doi: 10.1016/j.addr.2007.05.017 PMID: 18325628
3. Zhao L, Seth A, Wibowo N, Zhao C-X, Mitter N, et al. (2014) Nanoparticle vaccines. Vaccine 32: 327-337. doi: 10.1016/j.vaccine.2013.11.069 PMID: 24295808
4. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, et al. (2006) Pathogen recognition and development of particulate vaccines: does size matter? Methods 40: 1-9. PMID: 16997708
5. Singh M, Chakrapani A, O'Hagan D (2007) Nanoparticles and microparticles as vaccine-delivery systems. Expert review of vaccines 6: 797-808. PMID: 17931159
6. Roldão A, Mellado MCM, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. Expert review of vaccines 9: 1149-1176. doi: 10.1586/erv.10.115 PMID: 20923267
7. Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 31: 58-83. doi: 10.1016/j.vaccine.2012.10.083 PMID: 23142589
8. Correia-Pinto J, Csaba N, Alonso M (2013) Vaccine delivery carriers: Insights and future perspectives. International Journal of Pharmaceutics 440: 27-38. doi: 10.1016/j.ijpharm.2012.04.047 PMID: 22561794
9. Smith DM, Simon JK, Baker JR Jr (2013) Applications of nanotechnology for immunology. Nature Reviews Immunology 13: 592-605. doi: 10.1038/nri3488 PMID: 23883969
10. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert review of vaccines 9: 1095-1107. doi: 10.1586/erv. 10.89 PMID: 20822351
11. Dey AK, Srivastava IK (2011) Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert review of vaccines 10: 227-251. doi: 10.1586/erv.10.142 PMID: 21105782
12. Wibowo N, Chuan YP, Seth A, Cordoba Y, Lua LHL, et al. (2014) Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation. Vaccine 32: 3664-3669. doi: 10.1016/j.vaccine.2014.04.043 PMID: 24793947
13. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, et al. (2014) Bioengineering virus-like particles as vaccines. Biotechnology and bioengineering 111: 425-440. doi: 10.1002/bit.25159 PMID: 24347238
14. Noad R, Roy P (2003) Virus-like particles as immunogens. Trends in microbiology 11: 438-444. PMID: 13678860
15. Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LH, et al. (2013) Self-adjuvanting modular viruslike particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31: 1950-1955. doi: 10.1016/j.vaccine.2013.02.013 PMID: 23422147
16. Jennings GT, Bachmann MF (2008) The coming of age of virus-like particle vaccines. Biological chemistry 389: 521-536. PMID: 18953718
17. Grgacic EV, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40: 60-65. PMID: 16997714
18. Middelberg APJ, Rivera-Hernandez T, Wibowo N, Lua LHL, Fan Y, et al. (2011) A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29: 7154-7162. doi: 10.1016/j. vaccine.2011.05.075 PMID: 21651936
19. Wibowo N, Chuan YP, Lua LH, Middelberg AP (2013) Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chemical Engineering Science 103: 12-20.
20. Rose RC, White WI, Li M, Suzich JA, Lane C, et al. (1998) Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. Journal of virology 72: 6151-6154. PMID: 9621080
21. Murata Y, Lightfoote PM, Rose RC, Walsh EE (2009) Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virology Journal 6: 10. doi: 10.1186/1743-422X-6-10 PMID: 19166574
22. Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy D, et al. (2010) Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology, Immunotherapy 59: 1685-1696. doi: 10.1007/s00262-010-0895-0 PMID: 20652244
23. Schadlich L, Senger T, Gerlach B, Mucke N, Klein C, et al. (2009) Analysis of modified human papillomavirus type 16 L1 capsomeres: The ability to assemble into larger particles correlates with higher immunogenicity. Journal of Virology 83: 7690-7705. doi: 10.1128/JVI.02588-08 PMID: 19457985
24. Senger T, Schädlich L, Textor S, Klein C, Michael KM, et al. (2010) Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 28: 1583-1593. doi: 10.1016/j.vaccine. 2009.11.048 PMID: 20003923
25. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA (1998) Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. Journal of virology 72: 32-41. PMID: 9420197
26. Sapp M, Day PM (2009) Structure, attachment and entry of polyoma-and papillomaviruses. Virology 384: 400-409. doi: 10.1016/j.virol.2008.12.022 PMID: 19157477
27. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, et al. (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proceedings of the National Academy of Sciences 107: 13701-13706. doi: 10.1073/pnas.1007465107 PMID: 20615991
28. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, et al. (2012) PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release 161: 505-522. doi: 10.1016/j. jconrel.2012.01.043 PMID: 22353619
29. Thomas C, Rawat A, Hope-Weeks L, Ahsan F (2011) Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Molecular Pharmaceutics 8: 405-415. doi: 10.1021/mp100255c PMID: 21189035
30. Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S (2013) A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS One 8: e61885. doi: 10.1371/journal.pone.0061885 PMID: 23637922
31. Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. Journal of controlled release 85: 247-262. PMID: 12480329
32. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, et al. (2012) Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PloS one 7: e31472. doi: 10.1371/journal.pone.0031472 PMID: 22328935
33. Singh J, Pandit S, Bramwell VW, Alpar HO (2006) Diphtheria toxoid loaded poly-(e-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38: 96-105. PMID: 16442811
34. Chu C-H, Wang Y-C, Huang H-Y, Wu L-C, Yang C-S (2011) Ultrafine PEG-coated poly (lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications. Nanotechnology 22: 185601. doi: 10.1088/0957-4484/22/18/185601 PMID: 21415469
35. Roy S, Dixit CK, Woolley R, MacCraith BD, O'Kennedy R, et al. (2010) Novel multiparametric approach to elucidate the surface amine-silanization reaction profile on fluorescent silica nanoparticles. Langmuir 26: 18125-18134. doi: 10.1021/la103212d PMID: 21069990
36. Liew MWO, Chuan YP, Middelberg APJ (2012) High-yield and scalable cell-free assembly of virus-like particles by dilution. Biochemical Engineering Journal 67: 88-96.
37. Schussek S, Trieu A, Apte SH, Sidney J, Sette A, et al. (2013) Immunization with Apical Membrane Antigen 1 Confers Sterile Infection-Blocking Immunity against Plasmodium Sporozoite Challenge in a Rodent Model. Infection and Immunity 81: 3586-3599. doi: 10.1128/IAI.00544-13 PMID: 23836827
38. Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, et al. (2005) Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook: Springer. pp. 571-607.
39. Avgoustakis K (2004) Pegylated poly (lactide) and poly (lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Current drug delivery 1: 321-333. PMID: 16305394
40. Otsuka H, Nagasaki Y, Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Advanced drug delivery reviews 55: 403-419. PMID: 12628324
41. Souza J, Esparza I, Ferrer M, Sanz ML, Irache JM, et al. (2012) Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. BioMed Research International 2012.
42. Hillaireau H, Couvreur P (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cellular and Molecular Life Sciences 66: 2873-2896. doi: 10.1007/s00018-009-0053-z PMID: 19499185
43. Moyano DF, Goldsmith M, Solfiell DJ, Landesman-Milo D, Miranda OR, et al. (2012) Nanoparticle hydrophobicity dictates immune response. Journal of the American Chemical Society 134: 3965-3967. doi: 10.1021/ja2108905 PMID: 22339432
44. Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, et al. (2002) Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. International journal of pharmaceutics 245: 109-121. PMID: 12270248
45. Heinzel FP, Sadick MD, Holaday BJ, Coffman R, Locksley RM (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. The Journal of experimental medicine 169: 59-72. PMID: 2521244
46. Fiers W, De Filette M, Bakkouri KE, Schepens B, Roose K, et al. (2009) M2e-based universal influenza A vaccine. Vaccine 27: 6280-6283. doi: 10.1016/j.vaccine.2009.07.007 PMID: 19840661
47. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature medicine 5: 1157-1163. PMID: 10502819
48. Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, et al. (2013) M2e-Displaying Virus-Like Particles with Associated RNA Promote T Helper 1 Type Adaptive Immunity against Influenza A. PloS one 8: e59081. doi: 10.1371/journal.pone.0059081 PMID: 23527091
49. Zhou C, Zhou L, Chen Y-H (2012) Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 30: 3463-3469. doi: 10.1016/j.vaccine. 2012.03.021 PMID: 22446634
50. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Reviews Immunology 10: 787-796. doi: 10.1038/nri2868 PMID: 20948547
51. Champion JA, Mitragotri S (2009) Shape induced inhibition of phagocytosis of polymer particles. Pharmaceutical research 26: 244-249. doi: 10.1007/s11095-008-9626-z PMID: 18548338
52. Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, et al. (2013) Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS nano 7: 3926-3938. doi: 10.1021/nn3057005 PMID: 23631767
53. Foged C, Brodin B, Frokjaer S, Sundblad A (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. International journal of pharmaceutics 298: 315-322. PMID: 15961266
54. Kohli A, Alpar H (2004) Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. International journal of pharmaceutics 275: 13-17. PMID: 15081134
55. Sayin B, Somavarapu S, Li X, Thanou M, Sesardic D, et al. (2008) Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. International journal of pharmaceutics 363: 139-148. doi: 10.1016/j.ijpharm.2008.06.029 PMID: 18662762
56. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, et al. (1999) Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. Journal of controlled release 61: 233-240. PMID: 10469918
57. Zhang W, Wang L, Liu Y, Chen X, Liu Q, et al. (2014) Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 35: 6086-6097. doi: 10.1016/j.biomaterials.2014.04.022 PMID: 24780166
58. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801. PMID: 16497588
59. Fifis T, Mottram P, Bogdanoska V, Hanley J, Plebanski M (2004) Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 23: 258-266. PMID: 15531045
60. Yan S, Gu W, Xu ZP (2013) Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses. Journal of colloid and interface science 395: 1-10. doi: 10.1016/j.jcis.2012.11.061 PMID: 23312582
61. Vallhov H, Kupferschmidt N, Gabrielsson S, Paulie S, Strømme M, et al. (2012) Adjuvant properties of mesoporous silica particles tune the development of effector T cells. Small 8: 2116-2124. doi: 10. 1002/smll.201102620 PMID: 22511372